FROM PUBLIC EVENTS · 2026-11-15

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Global approvals · expansion Widening its overseas customers with a first European supply deal and registration work in Japan.

  • White-label supply agreement with a German company, its first entry into Europe. Source
  • Began preparing commercial use of a medium for a stem-cell therapy in Japan. Source

Roles often seen at this stageManufacturing & MSAT · BD & licensing · Research & development

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-15

Xcell Therapeutics

A maker of chemically defined cell-culture media for cell and gene therapies, widening supply to customers in China, Japan and Europe.

CellCor

Marketed

Media brand for stem cells, T cells, NK cells and exosomes, with plans announced to release four new media in 2026.

Completion reported

Entered Europe for the first time with a white-label supply agreement with a German company.

Announced

Began preparing local registration of a medium for a stem-cell therapy's commercial use in Japan.

Official role guide

Xcell Therapeutics careers

Current availability unconfirmed

Observed 2026-11-15

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 3

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 엑셀세라퓨틱스 "연내 신규 배지 4종 출시" ↗아시아경제 · Published 2026-09-15 · Sources checked 2026-11-15 · Original unavailable
  2. 엑셀세라퓨틱스, 獨 PL바이오 '화이트라벨' 계약…유럽 첫 진출 ↗비즈워치 · Published 2026-07-13 · Sources checked 2026-11-15 · Original unavailable
  3. 엑셀세라퓨틱스, 日 카티스템용 배지 상용화 준비 착수 ↗한국경제 · Published 2026-06-16 · Sources checked 2026-11-15 · Original unavailable